Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC (FOLFOX) combined with camrelizumab and apatinib for primary liver cancer with main portal vein tumor thrombus
ChiCTR2200062213Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jul 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, Rivoceranib, oxaliplatin, fluorouracil and folinic acid in hepatocellular carcinoma (HCC), sponsored by First Hospital of China Medical University. Primary endpoint: Progression-free survival. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
camrelizumabRivoceraniboxaliplatinfluorouracilfolinic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200062213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062213.